Drag a card by its title · ⚙ to size, swap or remove

The company

Itron, Inc.

ITRI · Nasdaq

Health CareLife-science toolsNot moving yetData-Center Infrastructure

ITRI stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 7.0% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 6
Industry in uptrend: 52% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $30.3M
Officials’ trades on record: 3

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

17 Apr – 16 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 1 people.

Who	Did	Amount	Traded
Suzan K. DelBene House: U.S. House ClerkWA01	soldjoint	$15k–$50k	9 Jun 2016filed 13 Jul 2016
Suzan K. DelBene House: U.S. House ClerkWA01	soldjoint	$1k–$15k	16 Mar 2016filed 15 Apr 2016
Suzan K. DelBene House: U.S. House ClerkWA01	boughtjoint	$15k–$50k	9 Apr 2015filed 10 May 2015

Insiders

Buy orders, 12 months0

Sale orders, 12 months76

Buyers · sellers0 · 8

Who	Did	Shares	Traded
Justin K. PatrickSVP, Device Solutions	sold	7,883at $97.36	3 Sep 2026filed 4 Sep 2026
Justin K. PatrickSVP, Device Solutions	sold	593at $97.36	3 Sep 2026filed 4 Sep 2026
Justin K. PatrickSVP, Device Solutions	sold	581at $97.36	3 Sep 2026filed 4 Sep 2026
Justin K. PatrickSVP, Device Solutions	sold	1,153at $97.36	3 Sep 2026filed 4 Sep 2026
Donald L. Reeves IIISVP, Outcomes	sold	283at $99.99	25 Aug 2026filed 26 Aug 2026
Thomas DeitrichPresident & CEO	sold	887at $98.79	24 Aug 2026filed 25 Aug 2026
Joan S. HooperSVP & CFO	sold	455at $98.79	24 Aug 2026filed 25 Aug 2026
John F. MarcoliniSVP, Networked Solutions	sold	331at $98.79	24 Aug 2026filed 25 Aug 2026
Justin K. PatrickSVP, Device Solutions	sold	222at $98.79	24 Aug 2026filed 25 Aug 2026
Laurie Ann Pulatie-HahnSVP, HR	sold	178at $98.79	24 Aug 2026filed 25 Aug 2026
Donald L. Reeves IIISVP, Outcomes	sold	329at $98.79	24 Aug 2026filed 25 Aug 2026
Christopher E. WareSVP, GC & Corp. Secretary	sold	200at $98.79	24 Aug 2026filed 25 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

News

Duquesne Light Company Builds Foundation for Grid Edge Intelligence with Itronmanilatimes.net · 14 Oct 2026 Itron and PG&E Advance Strategic Collaboration to Address Wildfire Mitigation with Grid Edge Intelligencemanilatimes.net · 13 Oct 2026 Itron and AT&T Business Expand Next-Generation Connectivity for Water and Gas Utilitiesmanilatimes.net · 12 Oct 2026 Itron Unveils Grid Edge Intelligence Catalyst: Feeder Reliability Solution to Help Utilities Improve Reliability Without Costly Grid Upgradesmanilatimes.net · 8 Oct 2026 Itron Advances Grid Reliability with New Outage Awareness and Fault Prevention Solutionmanilatimes.net · 7 Oct 2026 Should You Buy Itron (ITRI) Stock After Its Big APAC Expansion?insidermonkey.com · 28 Sep 2026 Consorcio de Aguas de Bilbao Bizkaia In Northern Spain Receives Itron's 3 Millionth Cyble 5 Modulewateronline.com · 21 Sep 2026

Everyone who traded it

Frank M. Jaehnert Director · last 1 Oct 20260 · 0

Jerome J. Lande Director · last 1 Oct 20260 · 1

Sanjay Mirchandani Director · last 1 Oct 20260 · 0

Santiago Perez Director · last 1 Oct 20260 · 0

Scott D. Drury Director · last 1 Oct 20260 · 0

Sheri Savage Director · last 1 Oct 20260 · 0

Timothy M. Leyden Director · last 1 Oct 20260 · 0

Justin K. Patrick SVP, Device Solutions · last 3 Sep 20260 · 29

Donald L. Reeves III SVP, Outcomes · last 25 Aug 20260 · 55

Christopher E. Ware SVP, GC & Corp. Secretary · last 24 Aug 20260 · 25

David Marshall Wright VP, Corp. Controller & CAO · last 24 Aug 20260 · 12

Joan S. Hooper SVP & CFO · last 24 Aug 20260 · 41

Same industry

OABI OmniAbLeading+65%

TXG 10x GenomicsLeading+60%

AVTR AvantorLeading+47%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+37%

CRL Charles River Laboratories InternationalLeading+35%

MASS 908 DevicesLeading+31%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202537.7%

Operating profit marginFY 2025 · to 31 Dec 202513.2%

Free cash flow marginFY 2025 · to 31 Dec 202516.2%

Return on capital employedFY 2025 · to 31 Dec 202511.6%

Cash conversionFY 2025 · to 31 Dec 2025135%

Debt to equityFY 2025 · to 31 Dec 20251.00×

Research spendFY 2025 · to 31 Dec 20258.7%

Share count trendFY 2025 · to 12 Feb 20260.0%

Cash and equivalentsFY 2025 · to 31 Dec 2025$1.0B

Free cash flowFY 2025 · to 31 Dec 2025$383.1M

Analyst forecasts

No analyst forecasts yet.